Company Overview: Pro Medicus Limited (ASX: PME) offers a full range of radiology IT software and services to hospitals, imaging centres and health care groups worldwide. The company purchased Visage Imaging in January 2009, transforming it into a global provider of leading-edge enterprise imaging solutions. The company was listed on ASX on 10 October 2000.

PME Details

Contract Wins & Geographical Expansion Aid PME: Recently, the company informed the market that, its wholly owned U.S. subsidiary, Visage Imaging, Inc., inked an 8-years contract with Inova Health System for a contract value of $32 million.

Contract Win Snapshot; Analysis by Kalkine Group

Emphasis on 1HFY22 Results:

• Higher Investments: In 1HFY22, PME made an ongoing R&D investment in Visage 7 Viewer, Visage Open Archive and Visage Workflow products, all of which added to the company’s performance. Moreover, the company continued to invest higher and expanded its geographical footprints via two key contracts with Novant Health and Allegheny Health.
  
  
• Geographical Diversification: The company has seen remarkable uplift in the North American business, which was a key contributor to 1HFY22 results. Also, its pipeline remains solid with a good spread of prospects in different markets. PME is looking forward to building on its presence in different geographies and is actively pursuing an increasing number of prospects within the enterprise imaging, integrated delivery network and corporate imaging centre markets.

Financial Performance; Analysis by Kalkine Group

Key Metrics: EBITDA margin for 1HFY22 stood at 72.5%, higher than the year-ago figure of 70.8%. The net margin for the year stood at 46.3%, compared to the previous corresponding period figure of 42.7%.

Profitability Profile; Analysis by Kalkine Group 

Top 10 Shareholders: The top 10 shareholders together form around 57.39% of the total shareholdings, while the top 4 constitutes the maximum holding. Hupert (Sam Aaron) and Hall (Anthony Barry) are holding a maximum stake in the company at 26% and 25.98%, respectively, as also highlighted in the chart below: 

Top 10 Shareholders; Analysis by Kalkine Group 

Risk Analysis:  The company is exposed to risks related to the complex regulatory landscape in the healthcare industry. Volatilities in the foreign currency, risk of losing new and existing market share, cyber security risks and increase in expenditure add to the woes.

Outlook: The company’s pipeline remained strong with an increased focus on developing new products and continued developing its Visage product sets. The year 2022 is anticipated to be a period of increased revenues from previously won transaction-based contracts. The company is focusing on growing its Visage 7.0 product to emphasise key market segments such as large Health Systems and Hospitals. PME aims to retain its market leadership by investing higher in innovative products.

Valuation Methodology: P/E Multiple Based Relative Valuation (Illustrative) 

Source: Analysis by Kalkine Group 

*% Premium/(Discount) is based on our assessment of the company’s NTM trading multiple after considering its key growth drivers, economic moat, stock's historical trading multiples versus peer average/median, and investment risks. 

Stock Recommendation: The stock of the company has been corrected by ~35.15% in the past six months. Currently, the stock is trading close to its 52-week low level of $39.08. The stock of the company has been valued using the P/E multiple-based illustrative relative valuation method and arrived at a target price of low double-digit upside (in % terms). The company might trade at some premium compared to its peers, consideration the anticipated benefits from major contracts, continued investment for product development and portfolio expansion, expected contribution from the North American region, sufficient returns to shareholders, etc. For the purpose of valuation, peers such as Nanosonics Ltd (ASX: NAN), Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH) and others have been considered. Taking into account the aforesaid fact, increase in top and bottom line in 1HFY22, diversified portfolio, geographical expansion, enhancing shareholder’s value, encouraging long-term outlook, current trading levels, and indicative upside in the valuation, we recommend a “Buy” rating on the stock at the closing market price of $40.23, up by ~0.299%, as on 18 May 2022.

PME Daily Technical Chart, Data Source: REFINITIV 

Technical Indicators Defined:-

Support: A level where-in the stock prices tend to find support if they are falling, and downtrend may take a pause backed by demand or buying interest.

Resistance: A level where-in the stock prices tend to find resistance when they are rising, and uptrend may take a pause due to profit booking or selling interest.

Stop-loss: It is a level to protect further losses in case of unfavourable movement in the stock prices.

Note 1: The reference data in this report has been partly sourced from REFINITIV.  

Note 2: Investment decision should be made depending on the investors’ appetite on upside potential, risks, holding duration, and any previous holdings. Investors can consider exiting from the stock if the Target Price mentioned as per the Valuation has been achieved and subject to the factors discussed above.

Disclaimer - This report has been issued by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and prepared by Kalkine and its related bodies corporate authorised to provide general financial product advice. Kalkine.com.au and associated pages are published by Kalkine.

Any advice provided in this report is general advice only and does not take into account your objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Statement or other offer document for the securities or other financial products referred to in Kalkine reports. You should obtain a copy of the relevant Product Disclosure Statement, Information Statement or offer document and consider the statement or document before making any decision about whether to acquire the security or product.

You should also seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice in this report or on the Kalkine website. Not all investments are appropriate for all people.

The information in this report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of information contained in its reports, newsletters and websites. All information represents our views at the date of publication and may change without notice.

Kalkine does not guarantee the performance of, or returns on, any investment. To the extent permitted by law, Kalkine excludes all liability for any loss or damage arising from the use of this report, the Kalkine website and any information published on the Kalkine website (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine hereby limits its liability, to the extent permitted by law, to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

On the date of publishing this report (referred to on the Kalkine website), employees and/or associates of Kalkine and its related entities do not hold interests in any of the securities or other financial products covered on the Kalkine website unless those persons comply with certain safeguards, procedures, and disclosures.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.